Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talsaclidine and Propranolol Airway Effects
NCT02264093Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 1999
- Primary completion
- Feb 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of talsaclidine in Alzheimer's disease (AD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Airway resistance, Specific conductance and 1 more. Started Nov 1999; status: completed.
02
Drugs
talsaclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02264093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02264093.